Summary Tamoxifen and 4-OH tamoxifen were used to reverse multidrug resistance (MDR) (Biedler et al., 1970) . Such multidrug resistance is associated with a decrease in intracellular drug accumulation attributed to a decreased rate of drug influx (Fojo et al., 1985) and/or an enhanced rate of efflux (Dano, 1973; Inaba et al., 1979) or both. The MDR phenotype has been shown to result from increased expression of a gene designated mdr (Gros et al., 1986) which is transcribed on to a 4.5-5.0 kb mRNA and the resultant protein product is the 170,000 dalton P-glycoprotein. The concomitant overexpression of P-glycoprotein has been consistently found in different MDR human (Rogan et al., 1984) and animal cell lines (Kartner et al., 1983 (Kartner et al., , 1985 (Ramu et al., 1984a) . The biochemical basis for some modulators of MDR is their ability to act as a substrate for the active efflux pump mediated by P-glycoprotein, competitively inhibiting the efflux of cytotoxic drugs which bind to P-glycoprotein, and thereby decreasing multidrug resistance (Safa et al., 1987) .
Development of resistance to cytotoxic cancer chemotherapeutic agents is a major impediment to effective treatment of human neoplastic diseases. To study this problem, in vitro models of the multidrug resistance (MDR) phenotype have been described where simultaneous cellular-resistance to a number of structurally and functionally unrelated 'natural' anticancer drugs occurred, following exposure to increasing concentrations of a single agent (Biedler et al., 1970) . Such multidrug resistance is associated with a decrease in intracellular drug accumulation attributed to a decreased rate of drug influx (Fojo et al., 1985) and/or an enhanced rate of efflux (Dano, 1973; Inaba et al., 1979) or both. The MDR phenotype has been shown to result from increased expression of a gene designated mdr (Gros et al., 1986) which is transcribed on to a 4.5-5.0 kb mRNA and the resultant protein product is the 170,000 dalton P-glycoprotein. The concomitant overexpression of P-glycoprotein has been consistently found in different MDR human (Rogan et al., 1984) and animal cell lines (Kartner et al., 1983 (Kartner et al., , 1985 .
Modulation of MDR in vitro has been demonstrated by several compounds such as verapamil and other calcium channel blockers (Tsuruo et al., 1981) , calmodulin inhibitors (Tsuruo et al., 1982) , amiodarone (Chauffert et al., 1986) and perhexilene maleate (Ramu et al., 1984a) . The biochemical basis for some modulators of MDR is their ability to act as a substrate for the active efflux pump mediated by P-glycoprotein, competitively inhibiting the efflux of cytotoxic drugs which bind to P-glycoprotein, and thereby decreasing multidrug resistance (Safa et al., 1987) .
A particular problem of using modulators of MDR clinically, is the inability to achieve plasma levels which are effective in reversing MDR in vitro without adverse side effects. For example, verapamil is effective in reversing MDR in vitro at concentrations 2.2 t1M, but maximal effect is seen between 5 and 10 M. However, maximum achievable levels of verapamil without major side-effects are 5 gM (Benson et al., 1985) . In addition, as verapamil binds substantially to alpha 1 acid glycoprotein (AAG), an acute phase plasma protein which increases non-specifically in cancer patients (Paxton et al., 1983) , the reversal of MDR by verapamil can be attenuated by the addition of AAG (Chatterjee et al., in preparation).
We were therefore interested in studying compounds where (a) reversal of multidrug resistance was possible, (b) concentrations of drug needed to reverse MDR in vitro were achievable in vivo, and (c) minimal or no binding to AAG occurred.
We have studied the effect of tamoxifen, an anti oestrogen, on suppression of adriamycin resistance. Ramu et al. (1984b) have shown that tamoxifen can reverse multidrug resistance in P388/Adr murine leukaemia cells. (Clinically, a daily administration of tamoxifen 20 mg twice daily has been shown by Patterson (1981) to have plasma levels in the range of 450 ng ml-' (1.2 tsM) after 12 weeks of treatment.) We have recently observed that high dose administration of tamoxifen (320 mg day-') produced plasma levels of up to 5 lM. Tamoxifen is 99% bound to albumin (Adam, 1981) and no binding with AAG has been reported. Since studies done in cell culture models of MDR are maintained in AAG free medium, we were interested in assessing tamoxifen induced reversal of multidrug resistance in the presence of AAG.
Tamoxifen is metabolised extensively and one of the major metabolites of tamoxifen is 4-hydroxy tamoxifen, which has a 100-fold greater binding affinity for oestrogen receptor and is a more potent anti-oestrogen than tamoxifen (Robertson et al., 1982; Jordan et al., 1977) . We therefore wanted to assess the potential of 4-hydroxy tamoxifen as a modulator of adriamycin resistance.
Materials and methods

Drugs
Adriamycin formulated for clinical use was obtained from Farmitalia, tamoxifen and 4-hydroxy tamoxifen from ICI (UK). Adriamycin was dissolved at 2 mM in water and aliquots stored at -20C. Tamoxifen and 4-hydroxy tamoxifen were dissolved in 95% ethanol at 10 mM and stored at 4°C. Ethanol at the final concentration present did not affect cell growth. Dilutions of drugs were made in growth medium and prepared just prior to use. 3H-tamoxifen (sp. activity 82 Ci mmol-') was obtained from New England Nuclear. Other chemicals were obtained from the Sigma Chemical Company.
Cell and culture conditions A CHO-Adrr cell line was isolated from wild-type (CHO-K1) cells by exposure to progressively increasing doses of adriamycin up to a maximum of 0.4 fig ml-'. Both cell lines were maintained in Hams FIO medium (Northumbria Biologicals) supplemented with 5% newborn calf serum, 5% fetal calf serum, antibiotics (streptomycin 100figml-', penicillin 100 units ml-'), nystatin 50 units ml-' and 3 mM glutamine. Cells were maintained as monolayer cultures at 37°C under 5% CO2. The CHO-Adri mutant was stable and maintained in drug-free medium. The CHO-Adrr mutant selected with adriamycin was simultaneously cross-resistant to vinca alkaloids, daunomycin, actinomycin D and colchicine, and has amplification of mdr sequences, high mdr expression by immunochemistry and high mRNA compared with the parent cell line.
Quantitation of drug effects
Drug sensitivity was assessed by a semi-automated colorimetric MTT assay, (Carmichael et al., 1987) . Briefly, cells were seeded on 96-well plates. Appropriate drug concentrations were added for 24 h, after which the cells were washed twice with phosphate buffered saline before being placed in 200 fil fresh medium for a further 48 h, 0.1 mg (50 gAl of 2 mg ml-') MTT was added to each well and incubated at 37C for 4 h.
The medium was then carefully aspirated, crystals solubilised in 100 gAl of dimethyl sulphoxide. Absorbences at 540 nm were immediately read on an ELISA multiskan reader. The IC5o was defined as the concentration of drug which caused 50% reduction in absorbance. The fold decrease in IC50 following addition of tamoxifen or 4-hydroxy tamoxifen was determined by dividing the IC50 for the adriamycin treated cells by that of adriamycin plus tamoxifen/4-hydroxy tamoxifen treated cells. A series of controls showed that cell numbers were linearly related to absorbance in the range 5 x 103 to 4 x 104, both in the presence and absence of adriamycin and tamoxifen. This absorbence was used in subsequent experiments.
Tamoxifen binding to AAG or albumin To measure binding to tamoxifen to AAG, increasing amounts of unlabelled tamoxifen (0-40 gM) plus 3H-labelled tamoxifen (100,000 c.p.m.) were incubated with 1 mg ml-' AAG for I h at 20°C. The reaction was terminated and unbound tamoxifen removed by addition of 0.4 ml of charcoal-dextran solution (0.5% w/v charcoal; 0.05% w/v dextran) for 15 min at 4°C. The solution was then centrifuged (4,000 r.p.m.) for 5 min at 4°C. Aliquots of 0.5 ml from the supernatant were counted on a scintillation counter. Nonspecific binding in the absence of AAG was less than 2%. To assess the binding of tamoxifen in cell-culture medium, binding to 4 mg ml-' albumin, which corresponded to 10% serum, was measured as above.
To measure the rate of binding, unlabelled tamoxifen, 10 gAM and 3H-labelled tamoxifen (100,000 c.p.m.) was incubated with 1 mg mlI AAG for varying time intervals and measured as above.
Drug accumulation studies
Exponentially growing cells were harvested by gentle agitation in 0.02% EDTA in PBS, washed by centrifugation and resuspended (1 x I07 cells ml-') in PBS, pH 7.4, containing 1% BSA and 10 mm glucose. Aliquots of 100 gAl of cells were preincubated for 10 min at 37°C. At time zero, 100 glI of medium containng 1 gAM adriamycin, with or without 1O gM tamoxifen, was added and incubated for varying time intervals. Influx was stopped by adding 4ml of ice-cold buffer (PBS containing 1% BSA), following by centriguation (3,000 r.p.m. x 10 min). The cells were washed twice with ice-cold buffer before the final cell pellet was solubilised in 1% SDS, 10 ml of liquid scintillant was added and radioactivity counted on a scintillation counter.
Statistics
Unpaired t tests were used to compare data points. Where differences are stated in the text there were significant at P<0.05 or higher degrees of significance. In all figures error bars are shown unless they fall within the size of the symbol.
Results
Effect of tamoxifen and 4-hydroxy tamoxifen on CHO-J and CHO-Adrr cells To examine the sensitivity of the CHO-K I and CHO-Adrr cells to tamoxifen and 4-hydroxy tamoxifen, the cells were exposed to appropriate drug concentrations for 24 h ( Figure Ib) . Therefore, both cell lines demonstrate similar sensitivity to the parent drug tamoxifen and its metabolite 4-hydroxy tamoxifen. To assess whether the presence of AAG could alter the cytotoxicity of tamoxifen and 4-hydroxy tamoxifen, 2 mg ml' AAG was added.
With the addition of 2 mg ml-' AAG to increasing concentrations of tamoxifen, the cells were completely protected and cell survival in both cell lines was increased to 80-100% of control. With 4-hydroxy tamoxifen, 2 mg ml-' AAG did not cause such a marked effect and the IC5o was decreased only 1.4-fold in CHO-KI cells (P<0.05) and 1.3-fold in the CHO-Adrr cells (P <0.05). Therefore, the parent compound and its metabolite interact with AAG to different extents. Tamoxifen binding to AAG To study the binding of tamoxifen to AAG, increasing concentrations of tamoxifen were incubated with either 1 mg ml' AAG or 4mgmlhl albumin (corresponding to 10% serum). Increased binding of tamoxifen to 1 mg ml' AAG occurred with increasing concentrations of tamoxifen ( Figure   2 ). At the highest concentration of 40 JAM, 30 nmol ml' are bound to AAG. The binding is non-specific and non-saturable. It occurs rapidly and is temperature-independent (Figure 3) . In contrast, with 4mgml-' albumin maximum binding of tamoxifen was 7.5 nmol ml-' and was saturable (Figure 2 ).
Effect of tamoxifen on adriamycin cytotoxicity Increasing concentrations of tamoxifen (1, 5 and 10 JiM ) that had little or no effect on cell growth enhanced the ability of adriamycin to inhibit cell growth in both cell lines ( Figure   4a ). The IC5o of adriamycin in CHO-Ki cells in the absence of tamoxifen was 0.24 gM. With the addition of 1, 5 and 10 JAM tamoxifen, the IC,o was decreased and the corresponding decrease was 1.8-fold, 2.4-fold and 4.8-fold respectively. Effect of 4-hydroxy tamoxifen on adriamycin cytotoxicity
To determine the effect of non-toxic concentrations of 4-hydroxy tamoxifen on adriamycin cytotoxicity, 5 AM or 10iJM 4-hydroxy tamoxifen was added to increasing adriamycin concentrations. In both CHO-KI and CHO-Adrr cell lines, the addition of 4-hydroxy tamoxifen shifted the absorbance curve to the left, the shift being greater in the CHOAdrr cells. In CHO-KI cells, the ICo of adriamycin was decreased 2.4 and 3.0-fold with 5JAM and 10IJM 4-hydroxy tamoxifen respectively (Figure 5a ), whereas in the CHO-Adrr cells the lC5( of adriamycin was decreased 2.0 and 13-fold with a similar concentration of JiM 4-hydroxy tamoxifen ( Figure Sb) . A 2-fold resistance to adriamycin remained with the highest concentration of 4-hydroxy tamoxifen, compared to the ICo of adriamycin alone (0.23 JAM) in the CHO-KI cell line.
Effect of tamoxifen on intracellular accumulation of adriamycin To evaluate whether the potentiation of adriamycin cytotoxicity by tamoxifen could be attributed to increased accumulation of adriamycin, both cell lines were incubated with '4C-adriamycin for various time periods and levels of intracellular adriamycin measured.
Over a 120min incubation period, there was a 1.5-2-fold The CHO-Adr cell line is 28-30-fold resistant to adriamycin, but both cell lines demonstrate equal sensitivity to tamoxifen and 4-hydroxy tamoxifen, which suggests that different cytotoxic targets exist. 4-hydroxy tamoxifen has a 100-fold higher anti-oestrogen activity than tamoxifen, but its cytotoxicity is similar to tamoxifen. We have also demonstrated in this study that the sensitivity to adriamycin in a MDR mutant (CHO-Adrr) can be increased by tamoxifen or its metabolite 4-hydroxy tamoxifen at concentrations which do not inhibit cell growth on their \, own. The degree of potentiation was greater in the CHO-A Adrr cell line than in the parent cell line, which is compatible with low degrees of mdr expression in the CHO-Ki cell line.
A This is similar to results with other modulators of MDR. The exact mechanism of modulation of adriamycin cytotoxicity is, however, unclear. Reddel et al. (1985) have demonstrated that the growth inhibitor effect of tamoxifen is oestrogen-irreversible at high 5.0 10.0 concentrations and they suggest the possibility of oestrogennoncompatible, anti-oestrogen-specific binding sites (AEBS) (Sutherland et al., 1980; Miller & Katzenellenbogen, 1983 (Paxton, 1983) . Both cell lines were accordingly exposed to equitoxic concentrations of adriamycin, in that concentration which reduced cell viability to 80-90% of control. Therefore, CHO-KI cells in the presence of an increasing concentration range of AAG (0-2 mg ml-') were exposed to 0.05 lM and CHO-Adrr cells to 1 gM adriamycin in the absence or presence of 10 gAM tamoxifen or 4-hydroxy tamoxifen. In CHO-KI cells (Figure 7a ), adriamycin at 0.05 J1M decreased cell viability to 86% of control and addition to 10 iM tamoxifen decreased it further to 37% of control. In CHO-Adrr cells, the cell viability was 82% of control in the presence of 1 t.M adriamycin and was decreased to 44% of control with the addition of 101JM tamoxifen. The addition of AAG (0-2 mg ml-') resulted in a gradual increase in cell viability, and finally, at 2 mg ml-' AAG, cell viability was similar to that of cells exposed to adriamycin alone.
Similarly, when 10JM 4-hydroxy tamoxifen was added to adriamycin, cell viability was decreased to 35% of control in CHO-KI cells and 35% of control in CHO-Adrr cells ( Figure  7b ). Addition of AAG increased cell survival and at the highest AAG concentration (2 mg ml-'), there was no significant difference in the cell viability of cells treated with adriamydin alone versus cells treated with adriamycin, 4-hydroxy tamoxifen and AAG. AAG did not independently affect cell growth or adriamycin cytotoxicity (results not shown). However, at concentrations of AAG < 1 mg ml' potentiation was still detectable.
Discussion
We have demonstrated a cytotoxic effect of tamoxifen and 4-hydroxy tamoxifen in the sensitive and resistant cell line. increased membrane rigidity reported in MDR cell membranes was decreased by the triparonol analogues, which accounted for faster diffusion of adriamycin and enhancement of its cytotoxicity. Foster et al. (1988) Horgan et al. (1986) have shown inhibition of PKC activity in vivo by tamoxifen. These results, therefore, suggest that inhibition of PKC may play an important role in the antitumour effect and modulation of MDR by tamoxifen and 4-hydroxy tamoxifen.
Another more likely target is calmodulin since the IC5o of tamoxifen is only 2 gM for this enzyme (Lam, 1984) compared with 25 tLM for IC50 of 4-hydroxy tamoxifen on PKC (O'Brian et al., 1988) .
AAG, which is normally absent from cell culture medium, has been shown to reverse the effect of verapamil-induced potentiation of adriamycin cytotoxicity (Chatterjee et al., in preparation). Verapamil binding to AAG has been shown by Gillis et al. (1985) . Since tamoxifen was reported to be 99% bound to albumin (Adam, 1981) and binding to AAG had not been suggested, we wanted to assess whether AAG, when present, could alter the reversal of adriamycin resistance by tamoxifen or 4-hydroxy tamoxifen. Our results have shown that AAG present at concentrations found at the higher range in cancer patients (0.8-2.0 mg ml-') can attenuate the reversal of multidrug resistance. However, AAG at levels found in the normal population and at the lower end of the cancer population allowed for enhancement of adriamycin cytotoxicity by the modulators used. Lien et al. (1989) recent- ly reported that tamoxifen is bound mainly to albumin, but only assessed binding of approximately 40 nM tamoxifen. In our study, 250-fold higher levels were used and it is clear that at these levels AAG markedly modifies the effects of tamoxifen and tamoxifen binds to AAG in the presence of albumin.
There was a residual 3-fold resistance of the CHO-Adrr mutant to adriamycin in the presence of tamoxifen. Recent studies have shown it is possible to increase the dose of adriamycin more than 2-fold, provided marrow is supported by haemopoetic growth factors (Bronchud et al., 1989) . Thus, a combined approach may be able to reverse resistance clinically. Although normal tissues may also be sensitised, the relatively greater effects of reversal agents on resistant cells with high levels of expression may still enhance the therapeutic/toxic ratio of anthracycline.
Possible clinical implications of this study are that tamoxifen and 4-hydroxy tamoxifen could prove effective cytotoxic agents as well as modulators of multidrug resistance; the limiting factor to their effectiveness could be high levels of AAG. It is conceivable that the free fraction of tamoxifen diffuses into tissues over several days to weeks and accumulates there, to exert its anti-oestrogen effect. Although 4-hydroxy tamoxifen is a minor metabolite of tamoxifen, it is much more potent (Jordan et al., 1977) . It has a lower degree of AAG binding, as assessed from the lack of protection by AAG against 4-hydroxy tamoxifen toxicity. 
